急性白血病患者化疗前后肿瘤相关物质群检测的临床意义

目的探讨恶性肿瘤相关物质群(Tumorsuppliedgroupoffactors,TSGF)检测在急性白血病(AL)患者疗效观察及预后判断中的价值。方法采用福建新大陆生物技术有限公司提供的TSGF检测试剂盒,对47例AL初治患者、8例复发患者及15例健康献血员血清TSGF水平进行测定。结果47例AL初治患者血清TSGF水平为78.47±14.71U/ml,8例复发患者血清TSGF水平为74.62±15.03U/ml,均明显高于对照组水平(51.29±7.54U/ml),差异非常显著(t=6.847,5.009,P<0.001);完全缓解(CR)组(11例)血清TSGF水平(56.15±9.18U/ml)明显下降,其水平与正常对照组比较无显著性差异(t=1.482,P>0.05);难治组血清TSGF水平(90.08±13.01U/ml)明显高于非难治组的水平(73.44±13.21U/ml),两者具有显著性差异(t=3.878,P<0.001)。结论TSGF对急性白血病患者疗效观察及预后判断有重要价值。

The clinical significance of determination of TSGF in acute leukemia before and after chemotherapy

Objective To study the clinical significance of determination of tumor supplied group of factors (TSGF) in acute leukemia(AL) before and after treatment. Methods Serum levels of TSGF were detected before and after treatment in patients with AL and compared with that of normal subjects. Results Serum levels of TSGF [(78.47±14.71)U/ml] in patients with AL before treatment and those[(74.62±15.03)U/ml]in relapsing patients were significantly higher than that [(51.29±7.54)U/ml]in normal controls(t=6.847, 5.009,P<0.001); Serum levels of TSGF[(56.15±9.18)U/ml]of 11 complete remission(CR) patients significantly decreased, the difference between CR group and normal group was not significant(t=1.482,P>0.05). Serum TSGF levels[(90.08±13.01)U/ml]of refractory group were significantly higher than that[(73.44±13.21)U/ml]of remission group, and the difference between them was significant(t=3.878,P<0.001).Conclusion Serum TSGF is a useful item for detecting effect of treatment and predicting prognosis in AL patients.[